(Q37997092)

26 August 2017

title

A novel treatment for glioblastoma: integrin inhibition (English)

1 reference

26 August 2017

1 reference

3

David A Reardon

1 reference

26 August 2017

4

Patrick Y Wen

1 reference

26 August 2017

Marc C Chamberlain

1

1 reference

26 August 2017

Timothy Cloughsey

series ordinal

2

1 reference

26 August 2017

publication date

1 April 2012

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

421-435

1 reference

Malignant gliomas in adults

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Recent advances in the treatment of malignant astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

NFKBIA deletion in glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Rechallenge with temozolomide in patients with recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Change in pattern of relapse after antiangiogenic therapy in high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Radiographic patterns of relapse in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Bevacizumab does not increase the risk of remote relapse in malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Role of angiogenesis in tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

RGD and other recognition sequences for integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Integrins: bidirectional, allosteric signaling machines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Genetic and cell biological analysis of integrin outside-in signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Integrins as "functional hubs" in the regulation of pathological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Integrins in cancer: biological implications and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

The biomechanical integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Integrins in angiogenesis and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Astrocytoma adhesion to extracellular matrix: functional significance of integrin and focal adhesion kinase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Molecular characterization of cell substratum attachments in human glial tumors relates to prognostic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Identification of human brain tumour initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Treatment resistance mechanisms of malignant glioma tumor stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Integrin alpha 6 regulates glioblastoma stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Activation of the HIF pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Integrin targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Treatment options for recurrent glioblastoma: pitfalls and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.188

21 January 2018

Identifiers

DOI

10.1586/ERN.11.188

1 reference

26 August 2017

1 reference